Tuesday, 17 July 2012
Center For HIV/AIDS Vaccine Immunology (CHAVI)
Haynes previously led the original Center for HIV/AIDS Vaccine Immunology (CHAVI) consortium, the grant for which just ended in June 2012. Center for HIV/AIDS Vaccine Immunology (CHAVI),
For its role in the new CHAVI-ID program, Duke will receive $19.9 million for the first year beginning this month, according to the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). AIDS vaccine,
Scripps Research Institute was also selected as a second center to receive CHAVI-ID grant funding.
The CHAVI-ID initiative overall may receive as much as $186 million or more over seven years. Duke may receive more than $139 million in total over the same time period. HIV 34 million,
“Duke is deeply honored to be selected again, as we now build on all the progress made in the initial CHAVI grant and now focus the effort on design of immunogens capable of preventing HIV transmission and protecting people worldwide,” said Victor J. Dzau, M.D., Chancellor for Health Affairs and CEO of Duke University Health System. Merck's experimental AIDS vaccine fails,
NIAID originally established CHAVI in response to recommendations of the Global HIV Vaccine Enterprise, a virtual consortium endorsed by world leaders at a G-8 summit in June 2004.
“We were privileged to have the CHAVI grant over the past seven years, and the work in this consortium helped us understand what needed to be done to make a successful AIDS vaccine,” said Haynes, who is also director of the Duke Human Vaccine Institute and the Frederic M. Hanes Professor of Medicine and Immunology. “The CHAVI-Immunogen Discovery grant will be used to learn how to do what we need to do.”
The CHAVI-ID grant now will focus on projects that are critical to creating the most effective vaccines for prevention, Haynes said.
Members of the Duke CHAVI-ID Scientific Leadership Group and their participating institutions who submitted the grant with Haynes are Andrew McMichael of Oxford University, UK; George Shaw, University of Pennsylvania; Bette Korber of Los Alamos National Laboratory; Garnett Kelsoe at Duke; and Joseph Sodroski and the late Norman Letvin of Harvard University.